spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Editorial

Jasmin Collier

Advertising

Max Garry 

 

 
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
RESEARCH AND DEVELOPMENT
Understanding the mAb structure-function relationship is a crucial factor in biosimilar development, points out Dr Terry Gray at Sartorius Stedim. This way, it is possible to significantly reduce wasted resources in the manufacturing process.


CELL-BASED RESEARCH
CellGenix’s Bernd Leistler reminds the pharma community that rules and regulations continue to tighten, and that it is important to maintain high quality levels in raw materials, in order to ensure the safety and efficacy of any therapy.
  Drug Discovery
BC Platforms’ Timo Kanninen talks collaboration and harmonisation, as he explains the need for pharma companies to get the most out of their data – he recommends the use of biobanks to achieve this.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


 

Industry Events

Clinical Innovation & Partnering World 2017

8-9 March 2017, Hilton Tower Bridge, London

This interactive two day conference will address how to bring the patient voice to the heart of your clinical strategy. We will examine and compare different partnering models and discuss change management strategies to facilitate innovation and improve relationships. There will be case studies from international thought leaders on disruptive technologies, data management, partnership models, communication strategies and outsourcing approaches. The 10th Clinical Innovation and Partnering World conference is your opportunity to engage and sit alongside the pioneers who are disrupting clinical research and getting medicines to patients faster.
More info >>

 
News and Press Releases

Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising


More info >>

air transport logo

 

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement